Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2025
0mins
Should l Buy SNY?
Source: Benzinga
Sanofi's Acquisition of Vicebio: Sanofi SA has agreed to acquire Vicebio Ltd for $1.15 billion, enhancing its vaccine portfolio with an early-stage combination vaccine candidate for RSV and hMPV, utilizing Vicebio’s 'Molecular Clamp' technology for improved vaccine development and distribution.
Impact on Respiratory Vaccines: This acquisition reinforces Sanofi's commitment to respiratory vaccines, complementing its existing offerings and allowing for easier manufacturing and distribution of liquid vaccines, while also not significantly impacting the company's financial guidance for 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 43.360
Low
57.00
Averages
79.36
High
119.07
Current: 43.360
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
Sanofi Reports Strong Q1 2026 Earnings with Significant Growth
- Earnings Beat: Sanofi's Q1 non-GAAP EPS of €1.88 exceeded expectations by €0.09, indicating sustained profitability and reinforcing investor confidence in the company's financial health.
- Significant Revenue Growth: The company reported Q1 revenue of €10.51 billion, a 6.3% year-over-year increase that surpassed market expectations by €280 million, reflecting strong market performance and rising product demand.
- Pharmaceutical Sales Surge: Pharma sales soared by 49.6% to €1.2 billion, primarily driven by the success of Ayvakit, ALTUVIIIO, and Sarclisa, showcasing the company's strength in innovative drug development.
- Optimistic Guidance: Sanofi affirmed that sales are expected to grow by a high single-digit percentage in 2026, with business EPS projected to grow slightly faster than sales before share buybacks, indicating a commitment to profitable growth.
See More
European Stocks Decline Amid New Coronavirus Mutation Concerns
- Market Sentiment Dips: Concerns over a new coronavirus mutation in South Africa have significantly impacted the German stock market, with European stocks expected to open lower on Thursday, including a projected 0.7% drop for the FTSE 100 and a 1.3% decline for the DAX.
- Oil Prices Surge: International benchmark Brent crude rose nearly 1.3% to $103.19 per barrel, driven by reports of the U.S. intercepting at least three Iranian oil tankers, which heightens uncertainty regarding the ongoing Middle East conflict and adds to market volatility.
- Germany's Economic Forecast Downgraded: The German Economics Ministry has halved its growth forecast for 2026 to just 0.5% and reduced the 2027 GDP estimate from 1.3% to 0.9%, citing the Iran conflict and the closure of the Strait of Hormuz as key factors affecting economic stability and rising costs for households and businesses.
- Inflation Expectations Rise: Officials project inflation to increase to 2.7% this year and 2.8% next year, which will have a lasting negative impact on consumers and businesses, further dampening market confidence amid economic uncertainty.
See More
Snowflake to Host Largest User Conference Yet
- Conference Scale: Snowflake will host its largest user conference ever from June 1-4, 2026, in San Francisco, expecting over 20,000 attendees, including customers, partners, and employees, to showcase how enterprises leverage Snowflake for AI transformation.
- Keynote Highlights: The opening keynote will feature a discussion between Anthropic Co-Founder Daniela Amodei and Snowflake CEO Sridhar Ramaswamy, focusing on the next generation of AI innovation and the central role of data in that transformation, drawing attention from global business and technology leaders.
- Rich Session Content: The conference will offer over 500 breakout sessions and 39 hands-on labs, allowing participants to explore how data, AI, and applications converge to drive intelligent, agent-driven experiences, thereby enhancing operational efficiency for enterprises.
- Industry-Specific Events: Snowflake Summit 26 will also introduce industry-specific sessions and executive panels, showcasing advanced AI use cases and real-world outcomes from leading organizations, further solidifying Snowflake's leadership in the AI Data Cloud space.
See More
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
Sanofi Reports Strong Q1 2026 Earnings with Significant Growth
- Earnings Beat: Sanofi's Q1 non-GAAP EPS of €1.88 exceeded expectations by €0.09, indicating sustained profitability and reinforcing investor confidence in the company's financial health.
- Significant Revenue Growth: The company reported Q1 revenue of €10.51 billion, a 6.3% year-over-year increase that surpassed market expectations by €280 million, reflecting strong market performance and rising product demand.
- Pharmaceutical Sales Surge: Pharma sales soared by 49.6% to €1.2 billion, primarily driven by the success of Ayvakit, ALTUVIIIO, and Sarclisa, showcasing the company's strength in innovative drug development.
- Optimistic Guidance: Sanofi affirmed that sales are expected to grow by a high single-digit percentage in 2026, with business EPS projected to grow slightly faster than sales before share buybacks, indicating a commitment to profitable growth.
See More
European Stocks Decline Amid New Coronavirus Mutation Concerns
- Market Sentiment Dips: Concerns over a new coronavirus mutation in South Africa have significantly impacted the German stock market, with European stocks expected to open lower on Thursday, including a projected 0.7% drop for the FTSE 100 and a 1.3% decline for the DAX.
- Oil Prices Surge: International benchmark Brent crude rose nearly 1.3% to $103.19 per barrel, driven by reports of the U.S. intercepting at least three Iranian oil tankers, which heightens uncertainty regarding the ongoing Middle East conflict and adds to market volatility.
- Germany's Economic Forecast Downgraded: The German Economics Ministry has halved its growth forecast for 2026 to just 0.5% and reduced the 2027 GDP estimate from 1.3% to 0.9%, citing the Iran conflict and the closure of the Strait of Hormuz as key factors affecting economic stability and rising costs for households and businesses.
- Inflation Expectations Rise: Officials project inflation to increase to 2.7% this year and 2.8% next year, which will have a lasting negative impact on consumers and businesses, further dampening market confidence amid economic uncertainty.
See More
Snowflake to Host Largest User Conference Yet
- Conference Scale: Snowflake will host its largest user conference ever from June 1-4, 2026, in San Francisco, expecting over 20,000 attendees, including customers, partners, and employees, to showcase how enterprises leverage Snowflake for AI transformation.
- Keynote Highlights: The opening keynote will feature a discussion between Anthropic Co-Founder Daniela Amodei and Snowflake CEO Sridhar Ramaswamy, focusing on the next generation of AI innovation and the central role of data in that transformation, drawing attention from global business and technology leaders.
- Rich Session Content: The conference will offer over 500 breakout sessions and 39 hands-on labs, allowing participants to explore how data, AI, and applications converge to drive intelligent, agent-driven experiences, thereby enhancing operational efficiency for enterprises.
- Industry-Specific Events: Snowflake Summit 26 will also introduce industry-specific sessions and executive panels, showcasing advanced AI use cases and real-world outcomes from leading organizations, further solidifying Snowflake's leadership in the AI Data Cloud space.
See More
